A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab Vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

Study on Treatment for Advanced Cervical Cancer

S
Sharon E. Robertson

Primary Investigator

Recruiting
18 years - 100 years
Female
Phase 3
1 participants needed
1 Location

Brief description of study

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding induction chemotherapy to the usual treatment of chemotherapy and radiation followed by maintenance may be more effective in treating patients with high risk, locally advanced cervical cancer.

Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:
IU Clinical Trials Office 
Phone: (317) 278-5632

Detailed description of study

Patients are randomized to 1 of 2 arms.

ARM 1:

CHEMORADIATION: Patients receive cisplatin intravenously (IV) once weekly (QW) for 5 weeks and pembrolizumab IV over 30 minutes every 3 weeks (Q3W) for 5 doses. Patients also undergo radiation therapy once daily 5 days per week for 25-29 treatments followed by brachytherapy up to twice per week for 4-5 treatments. Treatment given in the absence of disease progression or unacceptable toxicity

MAINTENANCE: Patients receive pembrolizumab IV over 30 minutes every 6 weeks (Q6W) for 15 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo positron emission tomography (PET) scan, computed tomography (CT) scan, chest x-ray and/or magnetic resonance imaging (MRI) and blood sample collection throughout the study.

ARM 2:

INDUCTION: Patients receive carboplatin IV and paclitaxel IV QW on weeks 1-3 and pembrolizumab IV over 30 minutes Q3W on weeks 1 for each cycle. Cycles repeat every 3 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.

CHEMORADIATION: Patients receive cisplatin IV QW for 5 weeks and pembrolizumab IV over 30 minutes every Q3W for 5 doses. Patients also undergo radiation therapy once daily 5 days per week for 25-29 treatments followed by brachytherapy up to twice per week for 4-5 treatments. Treatment given in the absence of disease progression or unacceptable toxicity

MAINTENANCE: Patients receive pembrolizumab IV over 30 minutes Q6W for 14 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo PET scan, CT scan, chest x-ray and/or MRI and blood sample collection throughout the study.

After completion of study treatment, patients are followed up every 3 months for 2 years then every 6 months for 3 years.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Advanced Cervical Squamous Cell Carcinoma, Advanced Cervical Adenocarcinoma, Cervical Cancer
  • Age: 18 years - 100 years
  • Gender: Female

Inclusion Criteria:

  • Patients must have pathologically confirmed newly diagnosed cervical cancer. Eligible pathologic types: squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma
  • Patients must have locally advanced cervical cancer (LACC) with T3 or T4 disease with or without lymph node involvement:
    • IIIA (T3aN0M0)
    • IIIB (T3bN0M0)
    • IIIC1(T3aN1M0, T3bN1M0)
    • IIIC2 (T3aN2M0, T3bN2M0)
    • IVA (T4aN0M0, T4aN1M0, T4aN2M0) No prior hysterectomy defined as removal of the entire uterus.
    • NOTE: prior partial/subtotal hysterectomy for reasons other than cervical cancer are eligible to participate in the study. No plan to perform a hysterectomy as part of initial cervical cancer therapy.

No paraaortic lymph node (PALN) metastases above the T12/L1 interspace.

  • Note: Nodal status can be confirmed by imaging (CT, MRI, or PET/CT), fine needle aspirate/core biopsy, extra peritoneal biopsy, laparoscopic biopsy, or lymphadenectomy.

Radiologic definition of lymph node staging:

  • N1:
    • One or more pelvic lymph nodes with short axis diameter of ≥ 15 mm (axial plane) by CT or MRI, and/or
    • One or more pelvic lymph nodes with short axis diameter of ≥ 10 mm and standardized uptake value maximum (SUVmax) ≥ 2.5 by fludeoxyglucose (FDG)-PET
  • N2:
    • One or more para-aortic lymph node with short axis diameter of ≥ 15 mm (axial plane) by CT or MRI, and/or
    • One or more para-aortic lymph node with short axis diameter of ≥ 10 mm and SUVmax ≥ 2.5 by FDG-PET
      • No prior definitive surgical, radiation, or systemic therapy for cervical cancer
      • No prior immunotherapy
      • No prior pelvic radiation therapy for any disease
      • Age ≥ 18
      • Eastern cooperative oncology group (ECOG) performance status of ≤ 2
      • Not pregnant and not nursing
      • Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3
      • Platelets ≥ 100,000 cells/mm^3
      • Hemoglobin ≥ 8 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobulin [Hgb] ≥ 8 g/dl is acceptable)
      • Creatinine clearance (CrCL) of ≥ 50 mL/min by the Cockcroft-Gault formula
      • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled)
      • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN
      • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
      • No active infection requiring parenteral antibiotics
      • No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacille Calmette Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines are live attenuated vaccines and are not allowed
      • No diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior registration
      • No active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
      • No history of (non-infectious) pneumonitis that required steroids, or current pneumonitis
      • No history of allergic reaction to the study agent(s) or compounds of similar chemical or biologic composition to the study agent(s) (or any of its excipients)

This study investigates treatment options for high risk locally advanced cervical cancer, where the cancer has spread to nearby tissues or lymph nodes. The study compares two approaches: one with induction chemotherapy using an investigational medication and chemotherapy, followed by chemoradiation and maintenance therapy, and the other with just chemoradiation and maintenance therapy. Chemotherapy involves drugs that kill or slow down cancer cells, while radiation therapy uses high energy to shrink tumors. Immunotherapy with an investigational medication may help the immune system fight cancer.

In this study, participants are divided into two study arms. In one arm, participants receive chemoradiation with cisplatin and an investigational medication, followed by maintenance therapy with the investigational medication. In the other arm, participants first receive induction chemotherapy with carboplatin and paclitaxel, alongside an investigational medication, followed by chemoradiation and maintenance therapy. Participants undergo various scans and tests, including PET, CT, and MRI, and provide blood samples throughout the study.

  • Who can participate: Adults 18 and older with specific types of high risk locally advanced cervical cancer can join. They must not have had prior surgery, radiation, or systemic therapy for cervical cancer and must meet health criteria like adequate blood counts and kidney function.
  • Study details: Treatment depends on the study group, including chemotherapy, radiation, and immunotherapy. Regular scans and tests will monitor health.
Updated on 16 Mar 2026. Study ID: CTO-NRG-GY037, 29780

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the Study Team